These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 7956010)

  • 1. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study.
    Jones RN; Marshall SA
    Diagn Microbiol Infect Dis; 1994 May; 19(1):33-8. PubMed ID: 7956010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.
    Frei R; Jones RN; Pignatari AC; Yamane N; Marco F; Hoban DJ
    Diagn Microbiol Infect Dis; 1994 Mar; 18(3):167-73. PubMed ID: 7924209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
    Jones RN; Salazar JC; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
    Jones RN; Pfaller MA; Doern GV; Erwin ME; Hollis RJ
    Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
    Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group.
    Xu Y; Chen M; Biedenbach DJ; Deshpande LM; Jones RN
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):135-42. PubMed ID: 10579094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.
    Johnson CC; Livornese L; Gold MJ; Pitsakis PG; Taylor S; Levison ME
    J Antimicrob Chemother; 1995 Jun; 35(6):765-73. PubMed ID: 7559188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE).
    Pfaller MA; Jones RN; Marshall SA; Coffman SL; Hollis RJ; Edmond MB; Wenzel RP
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):211-9. PubMed ID: 9327251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
    Wang FD; Liu IM; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Pfaller MA; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus.
    Tallis E; Rudensky B; Attias D; Raveh D; Schlesinger Y; Yinnon AM
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):121-6. PubMed ID: 10579092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
    Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes.
    Jones RN; Pfaller MA; Marshall SA; Hollis RJ; Wilke WW
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):187-92. PubMed ID: 9401811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of broad-spectrum beta-lactams in the philippines medical centers: role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group.
    Johnson DM; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):291-7. PubMed ID: 10668588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.
    Fung-Tomc J; Dougherty TJ; DeOrio FJ; Simich-Jacobson V; Kessler RE
    Antimicrob Agents Chemother; 1989 Apr; 33(4):498-502. PubMed ID: 2499250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital.
    Jean SS; Teng LJ; Hsueh PR; Ho SW; Luh KT
    J Antimicrob Chemother; 2002 Jan; 49(1):69-76. PubMed ID: 11751769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
    Spencer RC
    Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.